CA 19-9 anticorps

N° du produit ABIN3024244

Détail du produit anti-CA 19-9 anticorps

Antigène: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CA 19-9 est non-conjugé

Application: Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: PEG precipitation

Immunogène: Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.

Clone: 121SLE

Isotype: IgM kappa

Information d'application

Indications d'application: Optimal dilution of the CA19-9 antibody should be determined by the researcher.

1. No special pretreatment is required for the immunohistochemical staining of formalin-fixed, paraffin-embedded tissues
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format: incubate for 30 min at RT (2)

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the CA19-9 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Détails sur CA 19-9

Antigène: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Autre désignation: CA19-9 (CA 19-9 Produits)

Sujet: CA19-9, a carbohydrate epitope expressed on a high MW (>400  kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This mAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.